Literature DB >> 16288213

K-ras activation generates an inflammatory response in lung tumors.

H Ji1, A M Houghton, T J Mariani, S Perera, C B Kim, R Padera, G Tonon, K McNamara, L A Marconcini, A Hezel, N El-Bardeesy, R T Bronson, D Sugarbaker, R S Maser, S D Shapiro, K-K Wong.   

Abstract

Activating mutations in K-ras are one of the most common genetic alterations in human lung cancer. To dissect the role of K-ras activation in bronchial epithelial cells during lung tumorigenesis, we created a model of lung adenocarcinoma by generating a conditional mutant mouse with both Clara cell secretory protein (CC10)-Cre recombinase and the Lox-Stop-Lox K-ras(G12D) alleles. The activation of K-ras mutant allele in CC10 positive cells resulted in a progressive phenotype characterized by cellular atypia, adenoma and ultimately adenocarcinoma. Surprisingly, K-ras activation in the bronchiolar epithelium is associated with a robust inflammatory response characterized by an abundant infiltration of alveolar macrophages and neutrophils. These mice displayed early mortality in the setting of this pulmonary inflammatory response with a median survival of 8 weeks. Bronchoalveolar lavage fluid from these mutant mice contained the MIP-2, KC, MCP-1 and LIX chemokines that increased significantly with age. Cell lines derived from these tumors directly produced MIP-2, LIX and KC. This model demonstrates that K-ras activation in the lung induces the elaboration of inflammatory chemokines and provides an excellent means to further study the complex interactions between inflammatory cells, chemokines and tumor progression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16288213     DOI: 10.1038/sj.onc.1209237

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  141 in total

1.  Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.

Authors:  Anna Song; Wankyu Eo; Sookyung Lee
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

2.  Insulin receptor substrate-1 deficiency drives a proinflammatory phenotype in KRAS mutant lung adenocarcinoma.

Authors:  Heather E Metz; Julia Kargl; Stephanie E Busch; Kyoung-Hee Kim; Brenda F Kurland; Shira R Abberbock; Julie Randolph-Habecker; Sue E Knoblaugh; Jay K Kolls; Morris F White; A McGarry Houghton
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-20       Impact factor: 11.205

3.  Neutrophils are required for 3-methylcholanthrene-initiated, butylated hydroxytoluene-promoted lung carcinogenesis.

Authors:  Haris G Vikis; Andrew E Gelman; Andrew Franklin; Lauren Stein; Amy Rymaszewski; Jihong Zhu; Pengyuan Liu; Jay W Tichelaar; Alexander S Krupnick; Ming You
Journal:  Mol Carcinog       Date:  2011-10-17       Impact factor: 4.784

4.  Respiratory Enterovirus (like Parainfluenza Virus) Can Cause Chronic Lung Disease if Protection by Airway Epithelial STAT1 Is Lost.

Authors:  Yong Zhang; Dailing Mao; Shamus P Keeler; Xinyu Wang; Kangyun Wu; Benjamin J Gerovac; Laurie L Shornick; Eugene V Agapov; Michael J Holtzman
Journal:  J Immunol       Date:  2019-02-25       Impact factor: 5.422

5.  Interleukin 6, but not T helper 2 cytokines, promotes lung carcinogenesis.

Authors:  Cesar E Ochoa; Seyedeh Golsar Mirabolfathinejad; Venado Ana Ruiz; Scott E Evans; Mihai Gagea; Christopher M Evans; Burton F Dickey; Seyed Javad Moghaddam
Journal:  Cancer Prev Res (Phila)       Date:  2010-11-22

Review 6.  Update in lung cancer 2006.

Authors:  Sarita Dubey; Charles A Powell
Journal:  Am J Respir Crit Care Med       Date:  2007-05-01       Impact factor: 21.405

7.  Clinical significance of traditional clinical parameters and inflammatory biomarkers for the prognosis of patients with spinal chondrosarcoma: a retrospective study of 150 patients in a single center.

Authors:  Kehan Xu; Bo Li; Quan Huang; Dongjie Jiang; Haitao Sun; Nanzhe Zhong; Wei Wan; Haifeng Wei; Jianru Xiao
Journal:  Eur Spine J       Date:  2019-05-04       Impact factor: 3.134

8.  De novo lipogenesis represents a therapeutic target in mutant Kras non-small cell lung cancer.

Authors:  Anju Singh; Christian Ruiz; Kavita Bhalla; John A Haley; Qing Kay Li; George Acquaah-Mensah; Emily Montal; Kuladeep R Sudini; Ferdinandos Skoulidis; Ignacio I Wistuba; Vassiliki Papadimitrakopoulou; John V Heymach; Laszlo G Boros; Edward Gabrielson; Julian Carretero; Kwok-Kin Wong; John D Haley; Shyam Biswal; Geoffrey D Girnun
Journal:  FASEB J       Date:  2018-06-15       Impact factor: 5.191

9.  IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer.

Authors:  Mauricio S Caetano; Huiyuan Zhang; Amber M Cumpian; Lei Gong; Nese Unver; Edwin J Ostrin; Soudabeh Daliri; Seon Hee Chang; Cesar E Ochoa; Samir Hanash; Carmen Behrens; Ignacio I Wistuba; Cinthya Sternberg; Humam Kadara; Carlos Gil Ferreira; Stephanie S Watowich; Seyed Javad Moghaddam
Journal:  Cancer Res       Date:  2016-04-01       Impact factor: 12.701

10.  Immune Suppression Mediated by Myeloid and Lymphoid Derived Immune Cells in the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by HrasG12V and Pten Loss.

Authors:  Lee Ann Jolly; Nicole Massoll; Aime T Franco
Journal:  J Clin Cell Immunol       Date:  2016-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.